Sulfinpyrazone
From Wikipedia, the free encyclopedia
 |
|
|
Sulfinpyrazone
|
|
| Systematic (IUPAC) name | |
| 1,2-diphenyl-4-(2-phenylsulfinylethyl) pyrazolidine-3,5-dione | |
| Identifiers | |
| CAS number | |
| ATC code | M04 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C23H20N2O3S |
| Mol. mass | 404.483 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 98–99% |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP & thromboxane.
Sulfinpyrazone works by competitively inhibiting uric acid reabsorption in the proximal tubule.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||||||||||||||||||||||||||
|
||||||||
